EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials

Christopher R Cabanski, EnJun Yang, Mark D Stewart, Jeff D Allen, John E Connolly, Ute Dugan, Philip D Greenberg, Crystal L Mackall, Carl H June, Alexander Marson, Marcela V Maus, Antoni Ribas

Journal for ImmunoTherapy of Cancer · 2025-06 · 13 (6) · e011301

DOI: 10.1136/jitc-2024-011301 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 05.06.2025. Verfasst von Christopher R Cabanski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Parker Institute for Cancer Immunotherapy, San Francisco, California, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Neoplasms, Cell- and Tissue-Based Therapy, Immunotherapy, Adoptive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell-based gene therapies, including chimeric antigen receptor-T, T-cell receptor-T, and tumor-infiltrating lymphocyte therapies, have transformed the treatment landscape for certain cancers, yet their efficacy in solid tumors remains limited. Next-generation therapies aim to overcome biological barriers, enhance potency and safety, and streamline development timelines through innovative approaches. Recent advances in genome editing technologies have identified hundreds of gene edits that improve T-cell functionality in preclinical models. However, the limited direct translatability of these findings and the impracticality of testing each of the individual edits in a traditional clinical trial highlight the need for more efficient strategies. This article provides an overview of genome-wide screens that identify gene knockouts and knock-ins to enhance T-cell function and the limitations with translating these results to human trials. Next, we propose a novel clinical trial design for testing multiple gene modifications simultaneously within a single T-cell infusion product. This approach would enable head-to-head evaluation of edits in an internally controlled setting, accelerating the identification of promising candidate edits. Key considerations for Chemistry, Manufacturing, and Controls, non-clinical evaluation, and clinical protocols are discussed, with an emphasis on patient safety and ethical transparency. This framework is informed by insights shared at the “Unlocking Complex Cell-based Gene Therapies” workshop, held on May 6, 2024. Co-hosted by Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy, the event brought together participants from academia, the US Food and Drug Administration, and patient advocacy groups. By fostering collaboration among these stakeholders, this innovative approach aims to accelerate the development of effective cell-based therapies for complex diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyNeoplasmsCell- and Tissue-Based TherapyImmunotherapy, AdoptiveHumansClinical Trials as TopicGene Editing

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CARGene therapySolid tumorT cell Receptor - TCR

Autor:innen und Institutionen

  • Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • Friends of Cancer Research, Washington, District of Columbia, USA.
  • Division of Translational Science and Therapeutics, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Department of Immunology, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, USA.
  • Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.

Zitieren

APA

Cabanski, C. R., Yang, E., Stewart, M. D., Allen, J. D., Connolly, J. E., Dugan, U., Greenberg, P. D., Mackall, C. L., June, C. H., Marson, A., Maus, M. V., & Ribas, A. (2025). Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. Journal for ImmunoTherapy of Cancer, 13(6), e011301. https://doi.org/10.1136/jitc-2024-011301

Vancouver

Cabanski CR, Yang E, Stewart MD, Allen JD, Connolly JE, Dugan U, et al. Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. Journal for ImmunoTherapy of Cancer. 2025;13(6):e011301. doi:10.1136/jitc-2024-011301

BibTeX
@article{Cabanski2025,
  author = {Cabanski, Christopher R and Yang, EnJun and Stewart, Mark D and Allen, Jeff D and Connolly, John E and Dugan, Ute and Greenberg, Philip D and Mackall, Crystal L and June, Carl H and Marson, Alexander and Maus, Marcela V and Ribas, Antoni},
  title = {Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {6},
  pages = {e011301},
  doi = {10.1136/jitc-2024-011301}
}
Kostenlos starten →